Hyperion Therapeutics’ RAVICTI(TM) (glycerol phenylbutyrate) Liquid Receives FDA Approval for Treatment of Urea Cycle Disorders

[at noodls] – Anticipated market launch by end of April 2013 Patent allowance extends coverage to 2032 SOUTH SAN FRANCISCO, Calif., Feb. 1, 2013 (GLOBE NEWSWIRE) — Hyperion Therapeutics, Inc. (Nasdaq:HPTX) today announced … more

View todays social media effects on HPTX

View the latest stocks trending across Twitter. Click to view dashboard

See who Hyperion is hiring next, click here to view